Liposomes containing monophosphoryl lipid A and QS-21 serve as an effective adjuvant for soluble circumsporozoite protein malaria vaccine FMP013. 2017

Christopher J Genito, and Zoltan Beck, and Timothy W Phares, and Fanta Kalle, and Keith J Limbach, and Maureen E Stefaniak, and Noelle B Patterson, and Elke S Bergmann-Leitner, and Norman C Waters, and Gary R Matyas, and Carl R Alving, and Sheetij Dutta
Laboratory of Structural Vaccinology, Malaria Vaccine Branch, Walter Reed Army Institute of Research, 503 Robert Grant Avenue, Silver Spring, MD 20910, USA.

Malaria caused by Plasmodium falciparum continues to threaten millions of people living in the tropical parts of the world. A vaccine that confers sterile and life-long protection remains elusive despite more than 30years of effort and resources invested in solving this problem. Antibodies to a malaria vaccine candidate circumsporozoite protein (CSP) can block invasion and can protect humans against malaria. We have manufactured the Falciparum Malaria Protein-013 (FMP013) vaccine based on the nearly full-length P. falciparum CSP 3D7 strain sequence. We report here immunogenicity and challenge data on FMP013 antigen in C57BL/6 mice formulated with two novel adjuvants of the Army Liposome Formulation (ALF) series and a commercially available adjuvant Montanide ISA 720 (Montanide) as a control. ALF is a liposomal adjuvant containing a synthetic monophosphoryl lipid A (3D-PHAD®). In our study, FMP013 was adjuvanted with ALF alone, ALF containing aluminum hydroxide (ALFA) or ALF containing QS-21 (ALFQ). Adjuvants ALF and ALFA induced similar antibody titers and protection against transgenic parasite challenge that were comparable to Montanide. ALFQ was superior to the other three adjuvants as it induced higher antibody titers with improved boosting after the third immunization, higher serum IgG2c titers, and enhanced protection. FMP013+ALFQ also augmented the numbers of splenic germinal center-derived activated B-cells and antibody secreting cells compared to Montanide. Further, FMP013+ALFQ induced antigen-specific IFN-γ ELISPOT activity, CD4+ T-cells and a TH1-biased cytokine profile. These results demonstrate that soluble CSP can induce a potent and sterile protective immune response when formulated with the QS-21 containing adjuvant ALFQ. Comparative mouse immunogenicity data presented here were used as the progression criteria for an ongoing non-human primate study and a regulatory toxicology study in preparation for a controlled human malaria infection (CHMI) trial.

UI MeSH Term Description Entries
D007371 Interferon-gamma The major interferon produced by mitogenically or antigenically stimulated LYMPHOCYTES. It is structurally different from TYPE I INTERFERON and its major activity is immunoregulation. It has been implicated in the expression of CLASS II HISTOCOMPATIBILITY ANTIGENS in cells that do not normally produce them, leading to AUTOIMMUNE DISEASES. Interferon Type II,Interferon, Immune,gamma-Interferon,Interferon, gamma,Type II Interferon,Immune Interferon,Interferon, Type II
D008050 Lipid A Lipid A is the biologically active component of lipopolysaccharides. It shows strong endotoxic activity and exhibits immunogenic properties.
D008081 Liposomes Artificial, single or multilaminar vesicles (made from lecithins or other lipids) that are used for the delivery of a variety of biological molecules or molecular complexes to cells, for example, drug delivery and gene transfer. They are also used to study membranes and membrane proteins. Niosomes,Transferosomes,Ultradeformable Liposomes,Liposomes, Ultra-deformable,Liposome,Liposome, Ultra-deformable,Liposome, Ultradeformable,Liposomes, Ultra deformable,Liposomes, Ultradeformable,Niosome,Transferosome,Ultra-deformable Liposome,Ultra-deformable Liposomes,Ultradeformable Liposome
D008810 Mice, Inbred C57BL One of the first INBRED MOUSE STRAINS to be sequenced. This strain is commonly used as genetic background for transgenic mouse models. Refractory to many tumors, this strain is also preferred model for studying role of genetic variations in development of diseases. Mice, C57BL,Mouse, C57BL,Mouse, Inbred C57BL,C57BL Mice,C57BL Mice, Inbred,C57BL Mouse,C57BL Mouse, Inbred,Inbred C57BL Mice,Inbred C57BL Mouse
D004195 Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases. Animal Disease Model,Animal Disease Models,Disease Model, Animal
D005260 Female Females
D000276 Adjuvants, Immunologic Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund's adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity. Immunoactivators,Immunoadjuvant,Immunoadjuvants,Immunologic Adjuvant,Immunopotentiator,Immunopotentiators,Immunostimulant,Immunostimulants,Adjuvant, Immunologic,Adjuvants, Immunological,Immunologic Adjuvants,Immunological Adjuvant,Adjuvant, Immunological,Immunological Adjuvants
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000913 Antibodies, Protozoan Immunoglobulins produced in a response to PROTOZOAN ANTIGENS. Protozoan Antibodies
D001402 B-Lymphocytes Lymphoid cells concerned with humoral immunity. They are short-lived cells resembling bursa-derived lymphocytes of birds in their production of immunoglobulin upon appropriate stimulation. B-Cells, Lymphocyte,B-Lymphocyte,Bursa-Dependent Lymphocytes,B Cells, Lymphocyte,B Lymphocyte,B Lymphocytes,B-Cell, Lymphocyte,Bursa Dependent Lymphocytes,Bursa-Dependent Lymphocyte,Lymphocyte B-Cell,Lymphocyte B-Cells,Lymphocyte, Bursa-Dependent,Lymphocytes, Bursa-Dependent

Related Publications

Christopher J Genito, and Zoltan Beck, and Timothy W Phares, and Fanta Kalle, and Keith J Limbach, and Maureen E Stefaniak, and Noelle B Patterson, and Elke S Bergmann-Leitner, and Norman C Waters, and Gary R Matyas, and Carl R Alving, and Sheetij Dutta
April 1991, Lancet (London, England),
Christopher J Genito, and Zoltan Beck, and Timothy W Phares, and Fanta Kalle, and Keith J Limbach, and Maureen E Stefaniak, and Noelle B Patterson, and Elke S Bergmann-Leitner, and Norman C Waters, and Gary R Matyas, and Carl R Alving, and Sheetij Dutta
May 2019, mSphere,
Christopher J Genito, and Zoltan Beck, and Timothy W Phares, and Fanta Kalle, and Keith J Limbach, and Maureen E Stefaniak, and Noelle B Patterson, and Elke S Bergmann-Leitner, and Norman C Waters, and Gary R Matyas, and Carl R Alving, and Sheetij Dutta
June 2019, mSphere,
Christopher J Genito, and Zoltan Beck, and Timothy W Phares, and Fanta Kalle, and Keith J Limbach, and Maureen E Stefaniak, and Noelle B Patterson, and Elke S Bergmann-Leitner, and Norman C Waters, and Gary R Matyas, and Carl R Alving, and Sheetij Dutta
May 2019, mSphere,
Christopher J Genito, and Zoltan Beck, and Timothy W Phares, and Fanta Kalle, and Keith J Limbach, and Maureen E Stefaniak, and Noelle B Patterson, and Elke S Bergmann-Leitner, and Norman C Waters, and Gary R Matyas, and Carl R Alving, and Sheetij Dutta
April 2016, Natural products chemistry & research,
Christopher J Genito, and Zoltan Beck, and Timothy W Phares, and Fanta Kalle, and Keith J Limbach, and Maureen E Stefaniak, and Noelle B Patterson, and Elke S Bergmann-Leitner, and Norman C Waters, and Gary R Matyas, and Carl R Alving, and Sheetij Dutta
August 1990, Immunology letters,
Christopher J Genito, and Zoltan Beck, and Timothy W Phares, and Fanta Kalle, and Keith J Limbach, and Maureen E Stefaniak, and Noelle B Patterson, and Elke S Bergmann-Leitner, and Norman C Waters, and Gary R Matyas, and Carl R Alving, and Sheetij Dutta
June 1998, Infection and immunity,
Christopher J Genito, and Zoltan Beck, and Timothy W Phares, and Fanta Kalle, and Keith J Limbach, and Maureen E Stefaniak, and Noelle B Patterson, and Elke S Bergmann-Leitner, and Norman C Waters, and Gary R Matyas, and Carl R Alving, and Sheetij Dutta
October 2008, Cellular and molecular life sciences : CMLS,
Christopher J Genito, and Zoltan Beck, and Timothy W Phares, and Fanta Kalle, and Keith J Limbach, and Maureen E Stefaniak, and Noelle B Patterson, and Elke S Bergmann-Leitner, and Norman C Waters, and Gary R Matyas, and Carl R Alving, and Sheetij Dutta
September 1998, Expert opinion on investigational drugs,
Christopher J Genito, and Zoltan Beck, and Timothy W Phares, and Fanta Kalle, and Keith J Limbach, and Maureen E Stefaniak, and Noelle B Patterson, and Elke S Bergmann-Leitner, and Norman C Waters, and Gary R Matyas, and Carl R Alving, and Sheetij Dutta
June 2012, Expert review of vaccines,
Copied contents to your clipboard!